Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...

Factors Affecting Erythropoiesis

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...

Role of Hematopoietic Growth Factors

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024

Same author

The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration.

Kidney international·2024

Same author

Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states.

Clinical kidney journal·2024

Same author

Exploring the nexus: The place of kidney diseases within the cardiovascular-kidney-metabolic syndrome spectrum.

European journal of internal medicine·2024

Same author

Metabolically healthy obesity and chronic kidney disease risk: exploring the dynamics.

Panminerva medica·2024

Same author

Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024

Same journal

Epidemiology and multimorbidity in hemodialysis patients at a tertiary care center in northern Mexico: implications for hospital-based adverse outcomes.

Kidney & blood pressure research·2026

Same journal

The inflammatory milieu exacerbates Anemia of CKD: From the gut-kidney axis to bone marrow hematopoiesis inhibition.

Kidney & blood pressure research·2026

Same journal

Cystine-binding medication is poorly accessible for the treatment of cystinuria.

Kidney & blood pressure research·2026

Same journal

Infective endocarditis-associated glomerulonephritis caused by Streptococcus cristatus: A Case Report.

Kidney & blood pressure research·2026

Same journal

Simplified Subjective Global Assessment at Hemodialysis Initiation and Its Association with 2-Year Mortality and Hospitalization.

Kidney & blood pressure research·2026

Same journal

Long-Term Betaine Supplementation Increases Creatinine Clearance and Upregulates MAS and AT2 Receptor Expression in Spontaneously Hypertensive Rat Kidneys.

Kidney & blood pressure research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Stimulating erythropoiesis: future perspectives.

Ashraf Mikhail¹, Adrian Covic, David Goldsmith

¹Renal Unit, Morriston Hospital, Swansea, UK. ashraf.mikhail@swansea-tr.wales.nhs.uk

Kidney & Blood Pressure Research

|July 1, 2008

Summary

This summary is machine-generated.

New erythropoiesis-stimulating agents offer improved anemia correction for chronic kidney disease (CKD) patients. Future therapies may also provide cytoprotection, aiding in conditions like acute kidney injury.

More Related Videos

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Published on: September 9, 2014

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Related Experiment Videos

Last Updated: Jul 4, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Published on: September 9, 2014

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Area of Science:

Nephrology
Pharmacology
Biotechnology

Background:

Recombinant human erythropoietin (rHuEpo) has transformed anemia management in chronic kidney disease (CKD) for two decades.
Current treatments offer safe, long-term anemia correction, reducing reliance on blood transfusions.

Purpose of the Study:

To review innovative strategies for anemia correction in CKD patients.
To explore emerging erythropoiesis-stimulating agents and oral therapies.
To discuss the potential cytoprotective effects of these agents.

Main Methods:

Review of current literature and ongoing research in anemia management for CKD.
Analysis of novel erythropoiesis-stimulating agents (ESAs) and their mechanisms.
Investigation into the cytoprotective properties of ESAs beyond erythropoiesis.

Main Results:

Several new Epo-related molecules, including continuous Epo receptor activators and Epo mimetic peptides, are nearing clinical application.
Development of orally active antianaemic therapies is actively being pursued.
Erythropoiesis-stimulating agents demonstrate potential for cytoprotection by preventing cellular apoptosis.

Conclusions:

Future CKD anemia management will likely involve advanced ESAs with enhanced efficacy and novel administration routes.
The cytoprotective effects of ESAs present new therapeutic avenues for ischemia-reperfusion injury and acute kidney injury.
Ongoing research aims to bring these innovative treatments to clinical practice for improved patient outcomes.